• No results found

Individualized dosing of calcineurin inhibitors in renal transplantation Press, R.R.

N/A
N/A
Protected

Academic year: 2021

Share "Individualized dosing of calcineurin inhibitors in renal transplantation Press, R.R."

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Individualized dosing of calcineurin inhibitors in renal transplantation

Press, R.R.

Citation

Press, R. R. (2011, April 13). Individualized dosing of calcineurin inhibitors in renal transplantation. Retrieved from https://hdl.handle.net/1887/16715

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded

from: https://hdl.handle.net/1887/16715

Note: To cite this publication please use the final published version (if applicable).

(2)

Individualized Dosing of Calcineurin Inhibitors in Renal Transplantation

Rogier Press

Individualized Dosing of Calcineurin Inhibitors in Renal TransplantationRogier Press

(3)

Referenties

GERELATEERDE DOCUMENTEN

Peripheral blood cells were stained with HLA-A2.1 tetramers containing the tyrosinase368–376 peptide followed by staining with a panel of lineage antibodies, as described in

Blades and blade fragments seem to have been especially used for longitudinal motions, mainly on plant material (7/12). Flake and flake fragments are used in different motions on

The integrated approach used in this study, combining demographic, transplantation in- formation together with detailed exposure and genetic information in genes related to

tion versus effect relationship was observed between ciclosporin A concentration in whole blood and calcineurin activity in leukocytes obtained from 98 renal transplant recipients

Despite therapeutic drug monitoring of ciclosporin A (CsA) blood concentrations, renal transplant recipients still suffer from acute rejection episodes and nephrotoxicity.. Insight

De hoofdstukken 3 en 4 richten zich, voor respectievelijk tacrolimus en ciclosporine A, op het vinden van factoren die een rol spelen bij verschillen tussen personen in de mate

Het onderzoek hierin weergegeven is het resultaat van een plezierige, intensieve en zeker ook vruchtbare samenwerking van de afdelingen Klinische Farmacie & Toxicologie,

Ciclosporine A dient bij aanvang van therapie op basis van lichaamsgewicht te worden gedoseerd, de reeds bekende genetische markers voor de activiteit van betrokken cytochroom